Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||13%|
|1 Day Vol Adjusted Return||-1.7|
|1 Month Vol Adjusted Return||-4.5|
|3 Month Vol Adjusted Return||5.9|
|6 Month Vol Adjusted Return||2.0|
|20 Days SMA Price ZScore||-2.2|
|50 Days SMA Price ZScore||-0.1|
|12 -26 Days PPO||1.4|
|1 Month Average Short Volume Ratio||33.3|
|1 Day Volume Change ZScore||-0.8|
|1 Month Daily Vol||6.8|
electroCore,Inc.(Nasdaq: ECOR) closes patient enrollment study SAVIOR-1 to better understand clinical benefit of non-invasive vagus nerve stimulation
Extension maintains listing through June 3, 2023ROCKAWAY, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore will continue to be listed in the NHS Supply Chain catalogue for an additional two years through June 3, 2023. The original listing, which commenced on June 4, 2019, was scheduled to terminate on June 3, 2021. “We are pleased that this extension will allow NHS trusts and healthcare org...
Unfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality...
FDA clearance expands gammaCore label to include the acute and preventive treatment of migraine in adolescents 12 to 17 years of ageROCKAWAY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that on Friday, February 12, 2021, the company received Section 510(k) clearance from the Unites States Food and Drug Administration (FDA) of the company’s submission to expand the label of gammaCore nVNS to include t...
By John Vandermosten, CFA NASDAQ:ECOR READ THE FULL ECOR RESEARCH REPORT Since Our Last Update Since our previous full report on electroCore Inc. (NASDAQ:ECOR) in November, the company has provided several clinical, regulatory and commercial updates. In the clinical domain, electroCore published its study on noninvasive vagus nerve stimulation (nVNS) to reduce ileus after major colorectal
ROCKAWAY, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the completion of patient enrollment in SAVIOR-1, a prospective, randomized, controlled study evaluating vagus nerve stimulation in patients who exhibit respiratory symptoms due to COVID-19. This study is being conducted at the Hospital Clínico Universitario de Valencia, Spain. The SAVIOR-1 study enrolled 110 patients over 18 years of age with res...
ROCKAWAY, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper, entitled: “Non-invasive vagus nerve stimulation to reduce ileus after major colorectal surgery: Early development study” in the journal Colorectal Disease. The paper reports on the results of a parallel group, randomized controlled trial conducted at St. James’s University Hospital in Leeds, England. The s...
ROCKAWAY, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held virtually February 17-19, 2021. Event Details:Date: Wednesday, February 17Time: 12:30pm – 12:55pm ET A live webcast of the presentation will be available on the Investors section of the co...